<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35610460</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.</ArticleTitle><Pagination><StartPage>663</StartPage><EndPage>673</EndPage><MedlinePgn>663-673</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-022-01184-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis is a fatal progressive disease with a still unclear multi-factorial etiology. This study focused on the potential relationship between drug exposure and the development of amyotrophic lateral sclerosis by performing a detailed analysis of events reported in the FDA Adverse Event Reporting System database.</AbstractText><AbstractText Label="METHODS">The FDA Adverse Event Reporting System quarterly data (January 2004-June 2020) were downloaded and deduplicated. The reporting odds ratios and their 95% confidence intervals were calculated as a disproportionality measure. The robustness of the disproportion was assessed accounting for major confounders (i.e., using a broader query, restricting to suspect drugs, and excluding reports with amyotrophic lateral sclerosis as an indication). Disproportionality signals were prioritized based on their consistency across analyses (reporting odds ratio stability).</AbstractText><AbstractText Label="RESULTS">We retained 1188 amyotrophic lateral sclerosis cases. Sixty-two drugs showed significant disproportionality for amyotrophic lateral sclerosis onset in at least one analysis, and 31 had consistent reporting odds ratio stability, including tumor necrosis factor-alpha inhibitors and statins. Disproportionality signals from ustekinumab, an immunomodulator against interleukins 12-23 used in autoimmune diseases, and the anti-IgE omalizumab were consistent among analyses and unexpected.</AbstractText><AbstractText Label="CONCLUSIONS">For each drug emerging as possibly associated with amyotrophic lateral sclerosis onset, biological plausibility, underlying disease, and reverse causality could be argued. Our findings strengthened the plausibility of a precipitating role of drugs primarily through immunomodulation (e.g., tumor necrosis factor-alpha, ustekinumab, and omalizumab), but also by impacting metabolism and the musculoskeletal integrity (e.g., statins and bisphosphonates). Complement and NF-kB dysregulation could represent interesting topics for planning translational mechanistic studies on amyotrophic lateral sclerosis as an adverse drug effect.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaimari</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fusaroli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raschi</LastName><ForeName>Emanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldin</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Epidemiology and Statistics Unit, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vignatelli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Epidemiology and Statistics Unit, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nonino</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Epidemiology and Statistics Unit, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ponti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9244-9782</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. jessica.mandrioli@unimore.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. jessica.mandrioli@unimore.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poluzzi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>2P471X1Z11</RegistryNumber><NameOfSubstance UI="D000069444">Omalizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>FU77B4U5Z0</RegistryNumber><NameOfSubstance UI="D000069549">Ustekinumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069444" MajorTopicYN="N">Omalizumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069549" MajorTopicYN="N">Ustekinumab</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35610460</ArticleId><ArticleId IdType="doi">10.1007/s40264-022-01184-1</ArticleId><ArticleId IdType="pii">10.1007/s40264-022-01184-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;28. https://doi.org/10.1016/j.mayocp.2018.04.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis. Am J Manag Care. 2018;24:S327&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Calcium, mitochondria and the pathogenesis of ALS: the good, the bad and the ugly. Front Cell Neurosci. 2013;7:199. https://doi.org/10.3389/fncel.2013.00199 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00199</ArticleId><ArticleId IdType="pubmed">24198760</ArticleId><ArticleId IdType="pmc">3813898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:1010&#x2013;6. https://doi.org/10.1111/ene.14190 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14190</ArticleId><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, et al. No association between proton pump inhibitor use and ALS risk: a nationwide nested case&#x2013;control study. Sci Rep. 2020;10:13371. https://doi.org/10.1038/s41598-020-70373-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70373-8</ArticleId><ArticleId IdType="pubmed">32770128</ArticleId><ArticleId IdType="pmc">7414209</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Front Degener. 2018;19:538&#x2013;46. https://doi.org/10.1080/21678421.2018.1511731 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1511731</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkema EV, Feltelius N, Olsson T, Askling J. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment. Ann Rheum Dis. 2014;73:2061&#x2013;2. https://doi.org/10.1136/annrheumdis-2014-205622 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205622</ArticleId><ArticleId IdType="pubmed">25096786</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019;26:1355&#x2013;61. https://doi.org/10.1111/ene.13986 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13986</ArticleId><ArticleId IdType="pubmed">31087715</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschi E, Moretti U, Salvo F, Pariente A, Antonazzo IC, De Ponti F, et al. Evolving roles of spontaneous reporting systems to assess and monitor drug safety. IntechOpen. 2018. https://doi.org/10.5772/intechopen.79986 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/intechopen.79986</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonazzo IC, Raschi E, Forcesi E, Riise T, Bjornevik K, Baldin E, et al. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2018;17:869&#x2013;74. https://doi.org/10.1080/14740338.2018.1506763 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2018.1506763</ArticleId><ArticleId IdType="pubmed">30058390</ArticleId></ArticleIdList></Reference><Reference><Citation>Poluzzi E, Raschi E, Piccinni C, Ponti FD. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (FAERS). IntechOpen. 2012. https://doi.org/10.5772/50095 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/50095</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther. 2013;93:539&#x2013;46. https://doi.org/10.1038/clpt.2013.24 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.24</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitpain N, Devos D, Bagheri H, Rocher F, Gouraud A, Masmoudi K, et al. Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis? Fundam Clin Pharmacol. 2019;33:689&#x2013;94. https://doi.org/10.1111/fcp.12480 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12480</ArticleId><ArticleId IdType="pubmed">31058354</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia El Idrissi N, Bosch S, Ramaglia V, Aronica E, Baas F, Troost D. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13:72. https://doi.org/10.1186/s12974-016-0538-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0538-2</ArticleId><ArticleId IdType="pubmed">27056040</ArticleId><ArticleId IdType="pmc">4823861</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff TM, Lee JD, Noakes PG. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci USA. 2014;111:E3-4. https://doi.org/10.1073/pnas.1321248111 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1321248111</ArticleId><ArticleId IdType="pubmed">24381160</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SE, Hanton AM, Stefanou SN, Noakes PG, Woodruff TM, Lee JD. Revisiting the role of the innate immune complement system in ALS. Neurobiol Dis. 2019;127:223&#x2013;32. https://doi.org/10.1016/j.nbd.2019.03.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.03.003</ArticleId><ArticleId IdType="pubmed">30849511</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexion Pharmaceuticals. A phase 3, double-blind, randomized, placebo-controlled, parallel group, multicenter study with an open-label extension to evaluate the efficacy and safety of ravulizumab in patients with amyotrophic lateral sclerosis (ALS). 2021. https://clinicaltrials.gov/ct2/show/NCT04248465 . Accessed 18 May 2021.</Citation></Reference><Reference><Citation>Apellis Pharmaceuticals, Inc. A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS). 2021. https://clinicaltrials.gov/ct2/show/NCT04579666 . Accessed 18 May 2021.</Citation></Reference><Reference><Citation>Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, et al. NF-&#x3ba;B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J. 2018;37: e98697. https://doi.org/10.15252/embj.201798697 .</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798697</ArticleId><ArticleId IdType="pubmed">29875132</ArticleId><ArticleId IdType="pmc">6092622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bougea A, Anagnostou E, Stamboulis E, Kararizou E. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. Rev Neurol (Paris). 2014;170:228&#x2013;9. https://doi.org/10.1016/j.neurol.2013.11.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2013.11.004</ArticleId><ArticleId IdType="pubmed">24656415</ArticleId></ArticleIdList></Reference><Reference><Citation>Aj GA. Development of amyotrophic lateral sclerosis during ustekinumab use for refractory Crohn&#x2019;s disease. Ann Clin Case Rep. 2017;2:2.</Citation></Reference><Reference><Citation>Varan O, Kucuk H, Tufan A. Myasthenia gravis due to hydroxychloroquine. Reumatismo. 2016;67:125. https://doi.org/10.4081/reumatismo.2015.849 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2015.849</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. 2018;18:5&#x2013;18. https://doi.org/10.1038/nri.2017.97 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.97</ArticleId><ArticleId IdType="pubmed">28920587</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchi LF, Paoliello-Paschoalato AB, Oliveira RDR, Azzolini AECS, Kabeya LM, Donadi EA, et al. Activation status of peripheral blood neutrophils and the complement system in adult rheumatoid arthritis patients undergoing combined therapy with infliximab and methotrexate. Rheumatol Int. 2018;38:1043&#x2013;52. https://doi.org/10.1007/s00296-018-3997-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-018-3997-1</ArticleId><ArticleId IdType="pubmed">29464314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, et al. The kinase inhibitor imatinib mesylate inhibits TNF-&#x3b1; production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA. 2005;102:13622&#x2013;7. https://doi.org/10.1073/pnas.0501758102 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0501758102</ArticleId><ArticleId IdType="pubmed">16174751</ArticleId><ArticleId IdType="pmc">1224614</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V, Nozal V, Rojas-Prats E, Gil C, Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br J Pharmacol. 2021;178:1316&#x2013;35. https://doi.org/10.1111/bph.15221 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15221</ArticleId><ArticleId IdType="pubmed">32737989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener. 2020;21:5&#x2013;14. https://doi.org/10.1080/21678421.2019.1632346 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA&#x2019;s Adverse Event Reporting System. Drug Saf. 2018;41:403&#x2013;13. https://doi.org/10.1007/s40264-017-0620-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0620-4</ArticleId><ArticleId IdType="pubmed">29427042</ArticleId></ArticleIdList></Reference><Reference><Citation>Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:S52&#x2013;60. https://doi.org/10.1016/j.amjcard.2005.12.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2005.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020;15:38&#x2013;48. https://doi.org/10.2174/1574884714666190121154813 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574884714666190121154813</ArticleId><ArticleId IdType="pubmed">30666914</ArticleId><ArticleId IdType="pmc">7365998</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9:223&#x2013;8. https://doi.org/10.1080/17482960802031092 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802031092</ArticleId><ArticleId IdType="pubmed">18608105</ArticleId></ArticleIdList></Reference><Reference><Citation>Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 2008;62:88&#x2013;96. https://doi.org/10.1111/j.1742-1241.2007.01592.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-1241.2007.01592.x</ArticleId><ArticleId IdType="pubmed">18173814</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Front Degener. 2017;18:590&#x2013;7. https://doi.org/10.1080/21678421.2017.1336560 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1336560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, et al. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:861&#x2013;8. https://doi.org/10.1111/ene.13620 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13620</ArticleId><ArticleId IdType="pubmed">29512869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallette LE, Patten B, Cook JD, Engel WK. Calcium metabolism in amyotrophic lateral sclerosis. Dis Nerv Syst. 1977;38:457&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">862504</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters TL, Weibull CE, Fang F, Sandler DP, Lambert PC, Ye W, et al. Association of fractures with the incidence of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2017;18:419&#x2013;25. https://doi.org/10.1080/21678421.2017.1300287 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1300287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang K, Wang Z, Gan C, He P, Liang Y, et al. Effects of lead and cadmium co-exposure on bone mineral density in a Chinese population. Bone. 2014;63:76&#x2013;80. https://doi.org/10.1016/j.bone.2014.02.017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2014.02.017</ArticleId><ArticleId IdType="pubmed">24607944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Yi J, Bonewald L. Muscle-bone crosstalk in amyotrophic lateral sclerosis. Curr Osteoporos Rep. 2015;13:274&#x2013;9. https://doi.org/10.1007/s11914-015-0281-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11914-015-0281-0</ArticleId><ArticleId IdType="pubmed">26223903</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733&#x2013;48. https://doi.org/10.1002/med.21528 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12:526&#x2013;38. https://doi.org/10.1038/nrneurol.2016.111 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.111</ArticleId><ArticleId IdType="pubmed">27514291</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;4: CD004157. https://doi.org/10.1002/14651858.CD004157.pub2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004157.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins. 2017;9:260. https://doi.org/10.3390/toxins9090260 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins9090260</ArticleId><ArticleId IdType="pmc">5618193</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E, Raaphorst J, Twennaar MK, de Visser M, Schmand BA, de Haan RJ. The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry. 2016;87:611&#x2013;9. https://doi.org/10.1136/jnnp-2015-310734 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310734</ArticleId><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitrescu L, Constantinescu CS, Tanasescu R. Recent developments in interferon-based therapies for multiple sclerosis. Expert Opin Biol Ther. 2018;18:665&#x2013;80. https://doi.org/10.1080/14712598.2018.1462793 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2018.1462793</ArticleId><ArticleId IdType="pubmed">29624084</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Chi&#xf2; A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Group. Neurology. 2000;54:469&#x2013;74. https://doi.org/10.1212/WNL.54.2.469 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.2.469</ArticleId><ArticleId IdType="pubmed">10668716</ArticleId></ArticleIdList></Reference><Reference><Citation>Mpandzou G, A&#xef;t Ben Haddou E, Regragui W, Benomar A, Yahyaoui M. Vitamin D deficiency and its role in neurological conditions: a review. Rev Neurol (Paris). 2016;172:109&#x2013;22. https://doi.org/10.1016/j.neurol.2015.11.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2015.11.005</ArticleId><ArticleId IdType="pubmed">26867662</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos E, Mariosa D, Ingre C, Lundholm C, Wirdefeldt K, Roos PM, et al. Depression in amyotrophic lateral sclerosis. Neurology. 2016;86:2271&#x2013;7. https://doi.org/10.1212/WNL.000000000000267.1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.000000000000267.1</ArticleId><ArticleId IdType="pubmed">27164661</ArticleId><ArticleId IdType="pmc">4909561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisselmann G, Alisch D, Welbers-Joop B, Hatt H. Effects of quinine, quinidine and chloroquine on human muscle nicotinic acetylcholine receptors. Front Pharmacol. 2018;9:1339. https://doi.org/10.3389/fphar.2018.01339 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.01339</ArticleId><ArticleId IdType="pubmed">30515099</ArticleId><ArticleId IdType="pmc">6255974</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019;20:303&#x2013;9. https://doi.org/10.1080/21678421.2019.1587634 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Ticozzi N, Mandrioli J. Psychiatric symptoms in amyotrophic lateral sclerosis: beyond a motor neuron disorder. Front Neurosci. 2019;13:175. https://doi.org/10.3389/fnins.2019.00175 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00175</ArticleId><ArticleId IdType="pubmed">30914912</ArticleId><ArticleId IdType="pmc">6421303</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bastard Q, Al-Ghalith GA, Gr&#xe9;goire M, Chapelet G, Javaudin F, Dailly E, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther. 2018;47:332&#x2013;45. https://doi.org/10.1111/apt.14451 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14451</ArticleId><ArticleId IdType="pubmed">29205415</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuteja S, Ferguson JF. Gut microbiome and response to cardiovascular drugs. Circ Genomic Precis Med. 2019;12: e002314. https://doi.org/10.1161/CIRCGEN.119.002314 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGEN.119.002314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>